Table 1.
Patient characteristics *.
| Solid Cancer (n = 68) | Haematological Cancer (n = 38) |
HCWs (n = 57) | ||||
|---|---|---|---|---|---|---|
| % or Mean (SD) | % or Mean (SD) | % or Mean (SD) | ||||
| Exposed a | Unexp b | Exposed a | Unexp b | Exposed a | Unexp b | |
| SARS-CoV-2 status | n = 36 | n = 32 | n = 16 | n = 22 | n = 15 | n = 42 |
| Asymptomatic | 22.2% | NA | 31.3% | NA | 40.0% | NA |
| Mild | 52.8% | NA | 37.5% | NA | 46.7% | NA |
| Moderate | 8.3% | NA | 12.5% | NA | 0% | NA |
| Severe | 16.7% | NA | 12.5% | NA | 13.3% | NA |
| Critical | 0% | NA | 6.3% | NA | 0% | NA |
| Male sex | 41.7% | 53.1% | 43.8% | 40.6% | 13.3% | 11.9% |
| Age, mean (SD) | 58.8 (13.6) | 60.5 (12.7) | 57.9 (13.9) | 53.6 (20.4) | 37.5 (11.4) | 35.5 (10.7) |
| BMI, mean (SD) | 25.7 (6.1) | 25.6 (6.4) | 24.6 (6.9) | 24.1 (4.0) | 22.9 (0.0) | 24.2 (3.7) |
| Recent chemotherapy | 61.1% | 62.5% | 68.8% | 46.9% | 0% | 0% |
| Radiotherapy | 22.2% | 15.6% | 18.8% | 9.4% | 0% | 0% |
| Recent targeted therapy | 33.3% | 28.1% | 50% | 28.1% | 0% | 0% |
| Antihormonal treatment | 5.6% | 9.4% | 6.3% | 0% | 0% | 0% |
| Transplant | 0% | 0% | 25.0% | 15.6% | 0% | 0% |
HCWs: health care workers.SD: standard deviation. a All SARS-CoV-2 exposed individuals were included for CCG analysis. b Unexposed individuals were group-matched to exposed individuals based on age, gender, and cancer type in the case of cancer patients. NA: not applicable. * Additional patient comorbidities are represented in Supplementary Table S1.